06132 華健未來－Ｂ
HJ SCIENCE-B
HJ SCIENCE-B
| Register Close | 2026/06/17 IPO Closing in 5 Days |
| Listing Date | 2026/06/23 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
HJ Science Co., Ltd. is a clinical-stage biotech company founded by a team of industrial experts in 2017, dedicated to researching and developing therapies for autoimmune, metabolic and oncology diseases.
--
The Group have three Core Products, all of which are self-developed, small-molecule NMPA Category 1 innovative drugs.
HJ787 : a selective TYK2 inhibitor intended for the topical treatment of mild-to-moderate atopic dermatitis (AD), mild-to-moderate acne vulgaris (AV);
HJ178 : intended for type 2 diabetes and potentially overweight or obesity in the metabolic sector;
HJ891 : intended for the treatment of non-small-cell lung cancer
--
It held 29 issued patents including 12 patents in China and 17 patents overseas. With respect to Core Products, it had 2 issued patents and 2 pending patent applications for HJ891, 3 issued patents and 9 pending patent applications for HJ787 and 5 issued patents and 1 pending patent application for HJ178.
--
The years ended December 31, 2024 and 2025, the Group’s revenue was all derived from out-license and collaboration agreements with Junshi Biosciences and/or Junze Chuangyao.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 13.60M H shares |
| No. of International Offer Shares | 12.24M H shares |
| No. of HK Offer Shares | 1.36M H shares |
| Offer Price | $81.80 |
| Stock Code | 6132 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | CLSA Limited |
TIME TABLE
| Application Period | Jun 12 (Fri) - noon, Jun 17 (Wed) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jun 22 (Mon) |
| Result Announcement Date | On or before Jun 22 (Mon) |
| Result Announcement Date | On or before Jun 23 (Tue) |
| Dealings in Shares commence on | Jun 23, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $81.80 |
| Capitalization | 6.02B |
| NAV / share ($) | $19.35 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 81.8, the net proceeds raised would be HKD 1.02B, of which |
| 80.6% : Provide funding for ongoing and planned clinical research and development activities for pipeline products |
| 9.4% : Enhance research and development platform to strengthen innovation pipeline in immunology, metabolism and oncology |
| 5% : Build commercialization team, ensuring effective outreach and support for product launches |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).